Andera Partners has participated in a €51 million ($59 million) Series B financing round for its portfolio company Exciva GmbH, a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric conditions.
The round was co-led by Gimv and EQT Life Sciences, with participation from Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi VC, and existing investor LBBW.
Andera Partners was Exciva’s seed and Series A lead investor in 2021 and has now reinvested in the Series B.
The financing supports Exciva’s transition from early clinical development into Phase 2, marking a major value inflection point for the company.
The proceeds will primarily fund a Phase 2 clinical trial of Deraphan for the treatment of agitation in patients with Alzheimer’s disease.
Deraphan is a fixed-dose combination therapy consisting of:
The combination is designed to deliver:
A Phase 1 trial has already been completed, demonstrating that Deraphan is safe and well tolerated. The Phase 2 study will be conducted across Europe, the UK, the United States, and Canada.
Agitation is one of the most challenging neuropsychiatric symptoms of Alzheimer’s disease. It significantly impacts:
Despite its prevalence, safe and effective pharmacological options remain limited, making this a high-priority therapeutic area.
“We are delighted to have attracted both existing and new investors,” said François Conquet, CEO of Exciva. “If the Phase 2 results are positive, this would represent a meaningful advance in symptomatic treatment for Alzheimer’s patients.”
Raphaël Wisniewski, Partner at Andera Partners, highlighted the long-term vision:
“As founding investors, we are pleased to see this blue-chip investor syndicate support Exciva as it advances its differentiated candidate into Phase 2/3 development for agitation in Alzheimer’s disease.”
Following the Series B, Exciva’s board will include:
Founded in 2016 and based in Heidelberg, Germany, Exciva was established by Drs. Anton Bespalov, Hans Moebius, and Rao Vepachedu.
The company focuses on neuropsychiatric symptoms associated with Alzheimer’s disease dementia and other brain disorders, leveraging a discovery platform that combines CNS-active compounds into differentiated therapeutic candidates.
Founded nearly 25 years ago, Andera Partners manages over €5.1 billion across strategies including:
With offices across Paris, Antwerp, Madrid, Milan, and Munich, Andera supports companies through long-term, partnership-driven growth.